Human trials of indigenously developed Covid vaccines move to Phase 2: ICMR

Bhargava said once a safe and effective vaccine is developed, the focus should be on prioritisation and its fair distribution, roll-out and cold chain logistics

The Phase 1 human clinical trials of two Covid-19 vaccine candidates developed indigenously by Bharat Biotech in collaboration with ICMR and Zydus Cadila Ltd have been completed and the trials have moved to Phase 2, ICMR Director General Balram Bhargava said on Tuesday.

Addressing a press briefing, he said once a safe and effective vaccine is developed, the focus should be on prioritisation and its fair distribution, roll-out and cold chain logistics, stockpiling and training of people who would be administering the vaccine.

There are about 141 candidates that are being studied world over and 26 are in different phases